Cargando…
Hybridoma technology; advancements, clinical significance, and future aspects
BACKGROUND: Hybridoma technology is one of the most common methods used to produce monoclonal antibodies. In this process, antibody-producing B lymphocytes are isolated from mice after immunizing the mice with specific antigen and are fused with immortal myeloma cell lines to form hybrid cells, call...
Autores principales: | Mitra, Sanchita, Tomar, Pushpa Chaudhary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521504/ https://www.ncbi.nlm.nih.gov/pubmed/34661773 http://dx.doi.org/10.1186/s43141-021-00264-6 |
Ejemplares similares
-
Hybridoma technology: is it still useful?
por: Moraes, Jane Zveiter, et al.
Publicado: (2021) -
The application of hybridoma technology to the study of bovine immunoglobulins
por: Goldsby, R.A., et al.
Publicado: (1987) -
Hybridoma technology: new developments of practical interest
por: Samoilovich, Sergio R., et al.
Publicado: (1987) -
Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives
por: Parray, Hilal Ahmed, et al.
Publicado: (2020) -
Analysis of T cell hybridomas. IV. Characterization of inducible suppressor cell hybridomas
Publicado: (1983)